Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
Merck
Cantor Fitzgerald
Argus Health
QuintilesIMS
McKinsey
Citi
Moodys
Medtronic
Dow

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,976,870

« Back to Dashboard

Which drugs does patent 7,976,870 protect, and when does it expire?

Patent 7,976,870 protects XARTEMIS XR and is included in one NDA.

This patent has six patent family members in six countries.
Summary for Patent: 7,976,870
Title:Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
Abstract: Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.
Inventor(s): Berner; Bret (Half Moon Bay, CA), Louie-Helm; Jenny (Fremont, CA), Shell; John W. (Hillsborough, CA)
Assignee: Depomed, Inc. (Menlo Park, CA)
Application Number:10/769,574
Patent Claim Types:
see list of patent claims
Use; Dosage form; Delivery; Formulation;

Drugs Protected by US Patent 7,976,870

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Mallinckrodt Inc XARTEMIS XR acetaminophen; oxycodone hydrochloride TABLET, EXTENDED RELEASE;ORAL 204031-001 Mar 11, 2014 DISCN Yes No ➤ Subscribe ➤ Subscribe METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,976,870

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan I324075 ➤ Subscribe
Mexico PA04003930 ➤ Subscribe
Japan 2005507000 ➤ Subscribe
European Patent Office 1439826 ➤ Subscribe
Canada 2409552 ➤ Subscribe
World Intellectual Property Organization (WIPO) 03035041 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Chubb
Chinese Patent Office
Accenture
Daiichi Sankyo
Argus Health
Teva
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot